Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04341779

Simplifying Treatment and Monitoring for HIV (STREAM HIV)

This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and POC viral load (VL) monitoring in improving ART adherence, maintaining durable VL suppression, and improving retention in care among HIV-positive individuals initiating first-line tenofovir disoproxil fumarate (TDF)-based ART in South Africa.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

16 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal

Durban, KwaZulu-Natal, 4013, South Africa

About this study

This study will be a two-arm, open-label, randomized controlled superiority trial at an HIV clinic in Durban. HIV-positive individuals aged 16 years and above, who are initiating a tenofovir-based, first-line ART will be randomized to receive POC VL testing and POC TFV adherence testing, versus standard-of-care (SoC) viral load testing. The schedule for VL testing and management of VL test results will follow South African guidelines for HIV VL testing after ART initiation. 540 participants will be randomized (1:1) at ART initiation into the intervention arm (routine POC TFV adherence testing with POC VL monitoring) or the standard-of-care (SoC) arm (no objective TFV adherence testing and SoC VL monitoring).

Participants will be followed to compare concentrations between study arms at 24 weeks after ART initiation and a composite outcome of VL suppression and retention in care between the study arms at 72 weeks after ART initiation. The study will use process evaluation data, interviews and focus groups with patients and staff to assess implementation of the POC assays. Micro-costing will be conducted to estimate intervention costs.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • HIV-positive
  • ≥16 years old
  • Initiating a TDF-based, first-line ART regimen
  • Do not self-report being on an ART regimen in the prior month
  • Willing/able to provide written informed consent

Exclusion criteria

  • Does not plan to continue receiving HIV care at the CDC Clinic
  • Per the decision or opinion of the PI (for example, a clinically significant acute or chronic medical condition or circumstances that would make the patient unsuitable for participation or jeopardize the safety or rights of the participant

Treatment and study plan

Point-of-care viral load testing and tenofovir adherence testing

Combination Product

Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants

Primary outcomes

  1. Number of Participants With Viral Load Suppression (<200 Copies/ml) and Retained in Care at 72 Weeks

    Time frame: 72 weeks after ART initiation

    We will measure viral load by a laboratory-based reference assay, performed by the South African National Health Laboratory Services. Viral suppression will be defined as a viral load <200 copies/mL. This outcome will also include retention in care.

  2. Tenofovir Diphosphate Concentration Level >=700 Fmol/Punch in Dried Blood Spots

    Time frame: 72 weeks after ART initiation

    We will measure tenofovir-diphosphate concentrations in 3mm dried blood spots using liquid chromatography/tandem mass spectrometry.

Secondary outcomes

  1. Acceptability of Point-of-care Tenofovir and Viral Load Testing

    Time frame: 24 and 72 weeks after ART initiation

    We will assess acceptability of point-of-care tenofovir and viral load testing by conducting semi-structured in-depth interviews and focus group discussions with study participants.

  2. Cost-effectiveness of Providing Routine Point-of-care Tenofovir and Viral Load Testing as Compared to Standard-of-care Viral Load Monitoring

    Time frame: 24 and 72 weeks after ART initiation

    We will conduct a micro-costing of the costs associated with point-of-care tenofovir and viral load testing and will estimate the cost-effectiveness of the intervention using an existing individual-based, stochastic HIV model for KwaZulu-Natal for simulating health and economic outcomes.

Sponsors and collaborators

Lead sponsor

University of Washington

Other

Collaborators

  • Centre for the AIDS Programme of Research in South Africa
  • National Institute of Allergy and Infectious Diseases (NIAID)

Registry information

Official study title

Simplifying Treatment and Monitoring for HIV (STREAM HIV): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa

Important dates

Study start
2021
Primary completion
2025
Study completion
2026
First posted
Apr 10, 2020
Registry last updated
Feb 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.